Pharmacological inhibition of Eph receptors enhances glucose-stimulated insulin secretion from mouse and human pancreatic islets
- 9 March 2013
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 56 (6) , 1350-1355
Abstract
Type 2 diabetes is characterised by impaired glucose-stimulated insulin secretion (GSIS) from pancreatic islets. Since erythropoietin-producing hepatoma (Eph)–ephrin bidirectional signalling fine-tunes GSIS from pancreatic beta cells, we investigated Eph receptor tyrosine kinases (RTK) as potential drug targets for selectively increasing GSIS.Keywords
This publication has 20 references indexed in Scilit:
- Intramyocardial administration of chimeric ephrinA1‐Fc promotes tissue salvage following myocardial infarction in miceThe Journal of Physiology, 2011
- Eph/ephrin molecules—a hub for signaling and endocytosisGenes & Development, 2010
- A new collagenase blend increases the number of islets isolated from mouse pancreasIslets, 2009
- Discovery and structural analysis of Eph receptor tyrosine kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- Imatinib Mesylate Reduces Endoplasmic Reticulum Stress and Induces Remission of Diabetes indb/dbMiceDiabetes, 2009
- Eph-Ephrin Bidirectional Signaling in Physiology and DiseaseCell, 2008
- Ephs and Ephrins Keep Pancreatic β Cells ConnectedCell, 2007
- EphA-Ephrin-A-Mediated β Cell Communication Regulates Insulin Secretion from Pancreatic IsletsCell, 2007
- Upregulation of EphA2 during in vivo and in vitro renal ischemia-reperfusion injury: role of Src kinasesAmerican Journal of Physiology-Renal Physiology, 2006
- The islet β-cellThe International Journal of Biochemistry & Cell Biology, 2004